USA - NASDAQ:LSDI - CA54960E2033 - Common Stock
The current stock price of LSDI is 0.5139 USD. In the past month the price decreased by -40.24%. In the past year, price decreased by -95.53%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.63 | 887.25B | ||
| JNJ | JOHNSON & JOHNSON | 18.01 | 450.29B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.87 | 259.73B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.14 | 245.02B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 11.86 | 206.66B | ||
| MRK | MERCK & CO. INC. | 9.74 | 214.26B | ||
| PFE | PFIZER INC | 7.77 | 141.29B | ||
| SNY | SANOFI-ADR | 11.32 | 120.61B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.91B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 94.73B | ||
| ZTS | ZOETIS INC | 18.86 | 52.99B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 194.86 | 43.08B |
Lucy Scientific Discovery, Inc. operates as a psychotropics contract manufacturing company. The company is headquartered in Victoria, British Columbia. The company went IPO on 2023-02-09. The firm is engaged in researching, developing, and manufacturing psychotropic drugs. The firm is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. The company is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The firm is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.
LUCY SCIENTIFIC DISCOVERY IN
301-1321 Blanshard Street
Victoria BRITISH COLUMBIA CA
Employees: 0
Phone: 17784105195
Lucy Scientific Discovery, Inc. operates as a psychotropics contract manufacturing company. The company is headquartered in Victoria, British Columbia. The company went IPO on 2023-02-09. The firm is engaged in researching, developing, and manufacturing psychotropic drugs. The firm is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. The company is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The firm is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.
The current stock price of LSDI is 0.5139 USD. The price decreased by -23.29% in the last trading session.
LSDI does not pay a dividend.
LSDI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LSDI.
LUCY SCIENTIFIC DISCOVERY IN (LSDI) has a market capitalization of 904.46K USD. This makes LSDI a Nano Cap stock.
You can find the ownership structure of LUCY SCIENTIFIC DISCOVERY IN (LSDI) on the Ownership tab.
ChartMill assigns a fundamental rating of 2 / 10 to LSDI. LSDI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months LSDI reported a non-GAAP Earnings per Share(EPS) of -7.2. The EPS decreased by -96.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -263.59% | ||
| ROE | -13916.75% | ||
| Debt/Equity | 0 |
7 analysts have analysed LSDI and the average price target is 35.7 USD. This implies a price increase of 6846.88% is expected in the next year compared to the current price of 0.5139.